Introduction
Hepatitis B virus (HBV) infection results in major health problems worldwide, as more than 350 million people are chronically infected with HBV.
1,2 Persistent infection with HBV is associated with cirrhosis and hepatocellular carcinoma (HCC). 3 More than one million people die annually of liver cirrhosis and its complications, including HCC, annually. 1, 2 Lamivudine (2′,3′-deoxy-3′-thiacytidine) is the first therapeutic antiviral nucleoside analog with the ability to reduce serum HBV DNA by terminating viral DNA synthesis. 4 Although lamivudine is an effective agent for reducing serum HBV levels, 5, 6 long-term therapy may induce the emergence of lamivudine-resistant HBV mutants. [7] [8] [9] [10] [11] Furthermore, acute exacerbation of hepatitis (breakthrough hepatitis) may occur following the emergence of the HBV mutant. 12 The characteristic mutations in the HBV DNA polymerase gene (Pol) for lamivudine resistance were first reported by Honkoop et al. 9 The Pol gene region is divided into five subdomains, designated A through E. Lamivudineresistant HBV mutants carry mutations in the LLA motif of domain B, and in the YMDD motif of domain C. 13 In the YMDD motif, methionine is substituted by valine or isoleucine via point mutation, whereas leucine in the LLA motif of domain B is substituted by methionine in lamivudine-resistant HBV mutants. These mutations hinder the binding of lamivudine to the Pol gene product. [14] [15] [16] Three classes of mutations are observed in the Pol region: M204V + L180M (YVDD); M204I alone (YIDD); and M204I + L180M (LMA). 7, 17, 18 Early detection of these mutants can aid clinicians by facilitating improved management and the early introduction of alternative treatments. 19, 20 The detection of HBV mutants is performed via methods such as sequencing, and polymerase chain reaction followed by a restriction fragment length polymorphism (PCRbridization (FBH) assay employing a LightCycler for the detection of lamivudine-resistant HBV mutants has been reported. 11, 23 Via this procedure, two different mutations in the YMDD and LLA motifs can be analyzed simultaneously using two sets of probes. 11, 23 In the current study, we evaluated the clinical usefulness of the FBH assay for detecting mutations in the YMDD and LLA motifs by analyzing samples from patients before and during lamivudine therapy. Furthermore, we estimated the proportion of mutant to wild-type virus from the melting peak height ratios.
Patients and methods

Patients
Twenty-seven patients with elevated serum transaminase and HBV DNA levels who were hepatitis B surface antigen (HBsAg) positive were treated with lamivudine at the Department of Gastroenterology and Hepatology at Okayama University Hospital between 1998 and 2003. All patients orally received 100 mg of lamivudine daily for more than 12 months. The diagnosis of chronic hepatitis B was based on histologic examination, while cirrhosis was diagnosed histologically or clinically. The criteria for the clinical diagnosis of cirrhosis included evidence of portal hypertension such as hypersplenism, esophageal varices, ascites, and hepatic encephalopathy, associated with imaging features suggestive of cirrhosis during ultrasonography or computed tomography. Informed consent was obtained from each patient.
Serological markers and determination of serum HBV DNA levels
Hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe) were detected via chemiluminescent enzyme immunoassay (Lumipulse HBeAg and HBeAb; Fujirebio, Tokyo, Japan). Serum HBV DNA levels in all patients before and during lamivudine treatment were measured via quantitative PCR (Amplicor HBV monitor assay; Roche Diagnostics, Basel, Switzerland). The HBV levels were expressed as log copies per milliliter, and the upper and lower detection limits of the assay were 7.6 and 2.6 log copies/ml, respectively.
Serum samples and extraction of HBV DNA
Serum samples were obtained from all patients before and during lamivudine treatment, and stored at −20°C until use. HBV DNA was extracted from 200 µl of each sample using a QIAmp DNA Mini nucleic acid extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
Detection of HBV mutants
Pol gene region DNA was amplified by PCR, and mutations in the YMDD and LLA motifs were simultaneously analyzed by fluorescence resonance energy transfer probes using a LightCycler (Roche Diagnostics). PCR primers and fluorescence hybridization probes were designed as shown in Fig 1. The primers used for PCR were HBVPF (5′-ACT GCA GTT GTA TTC C-3′; nucleotides 591 to 606) and HBVPR (5′-CAT ACT TTC CAA TCA ATA GG-3′; nucleotides 989 to 970). These primers encompass both the B and C domains of the HBV DNA polymerase gene. Two hybridization probes were synthesized and labeled with fluorescein. For domain C, a longer probe, APC-787 (5′-GGG ACT CAA GAT GTT GTA CAG ACT TGG CCC CCA A-3′; nucleotides 787 to 754) was 3′-labeled with fluorescein isothiocyanate (FITC) and served as the "anchor" probe, while a shorter probe, MPC-752 (5′-ACC ACA TCA TCC ATA TAA CTG AA-3′; nucleotides 752 to 730) was 5′-labeled with LC-Red 640 and served as the "detection" probe. For domain B, the longer APB-711 (5′-AGC CCT ACG AAC CAC TGA ACA AAT GGC ACT AGT A-3′; 711 to 678) was 3′-labeled with FITC, and served as the anchor probe, while the shorter MPB-676 (5′-ACT GAG CCA TGA GAA ACG G-3′; 676 to 658) was 5′-labeled with LCRed 750, and served as the detection probe for domain B analysis. The sequence of MPC 752 is specific to the nucleotide sequence of YMDD, while MPB-676 is specific to that of the LMA mutant.
The reaction was performed in a total volume of 20 µl, containing 10 µl of DNA template extracted from patient serum, 4 mM MgCl 2 , 0.32 µl of anti-Taq antibody (Toyobo, Tokyo, Japan), 25 µM of each primer (HBVPF and HBVPR), each probe, and the DNAMaster Hybridization Probes (Roche Diagnostics), containing Taq DNA polymerase, reaction buffer, and a dNTP mix. Samples were loaded into composite glass disposable capillaries (Roche Diagnostics), centrifuged, and placed in the LightCycler sample carousel. Cycling conditions were as follows: after initial denaturation at 95°C for 2 min, 55 cycles were performed at 95°C for 0 s, 51°C for 15 s, and 72°C for 30 s, with a ramping time of 20°C/s. After completion of the amplification process, a melting curve was generated by denaturing at 95°C for 0 s, followed by immediate cooling to 40°C at a ramp rate of 20°C/s. After holding at 40°C for 10 s, samples were slowly heated to 75°C at a ramp rate of 0.2°C/s with continuous fluorescence measurement.
The LightCycler instrument is an integrated thermal cycler and fluorimeter that performs real-time PCR product detection by measuring the fluorescence change in spectral windows. It is equipped with a threechannel fluorimeter, which detects emitted light with wavelengths of 530, 640, and 710 nm. The 530-nm channel detects the light emitted by fluorescein. The 640-nm channel is optimized to detect light emitted by LC-Red 640, whereas the 710-nm channel is optimized to detect light emitted by LC-Red 705. When both the anchor probe and detection probe hybridize with the PCR product within a one-nucleotide interval, fluorescence is emitted by fluorescence resonance energy transfer. Owing to the great stability of the anchor probe, a loss of fluorescence occurs as the shorter detection probe melts off the template as the temperature gradually increases. During this process, declining fluorescence was continuously monitored, and a melting curve analysis of the data was performed using the LightCycler analysis software v3.5 (Roche Diagnostics). Melting curves were converted to melting peaks (Tm) by plotting the negative derivative of fluorescence with respect to temperature (−dF/dT). The presence of a single-base mismatch under the detection probe results in a shift in the melting temperature to a temperature lower than that for the probe-specific sequence.
Detection sensitivity of the mutant
In order to evaluate the assay's quantitative capability and to determine the detection sensitivity for mutant HBV, mixtures of wild-type and mutant plasmid DNA were analyzed via a melting curve analysis, at ratios of (mutant/wild-type virus) 80 : 20, 60 : 40, 40 : 60, 20 : 80, 10 : 90, 5 : 95, 2 : 98, 1 : 99, and 0 : 100. Receiver operating characteristic (ROC) curves were applied to find the best sensitivity and specificity cut-off values for the presence of the YIDD mutant. Linear regression analysis was performed between the melting peak height ratios and the ratios of mutant/wild-type plasmid DNA.
DNA sequencing
HBV DNA extracted from patient serum was amplified by PCR, using a thermal cycler with primer set HBVPF and HBVPR. The PCR mixture consisted of a Pfu buffer, 25 mM MgCl 2 , 2.5 mM dNTP mix, 10 µM of each primer, and 1.25 units of Pfu (Stratagene, La Jolla, CA, USA). Regarding the temperature conditions for PCR, an initial denaturation was undertaken at 95°C for 2 min, followed by the application of 35 cycles of denaturation at 95°C for 30 s, annealing at 57°C for 30 s, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min. The DNA fragment resulting from PCR using these primers was a 399-bp product encompassing both the B and C domains of the HBV DNA Pol gene. Amplified PCR products were cloned using the TOPO TA-cloning kit (Invitrogen, Carlsbad, CA, USA), and were then transformed into DH5α Escherichia coli (Toyobo, Tokyo, Japan) according to the manufacturer's protocol. Plasmids were purified using a plasmid minikit (Qiagen). Sequencing was performed directly on amplified products and/or on a number of individual plasmid clones by a primer set (HBVPF and HBVPR), using a DNA sequencer 3100-Avant Genetic Analyzer (ABI, Foster City, CA, USA). 
Statistical analysis
Quantitative variables are expressed as means ± SD, or medians, when the distribution was not normal. Qualitative variables are expressed as percentages. The cumulative incidences of YMDD mutant development, reappearance or increase of HBV DNA, and breakthrough hepatitis were calculated using the KaplanMeier technique, and evaluated from the start point of lamivudine until the last visit. To determine the factors associated with the development of a YMDD mutant, a univariate analysis (Cox's proportional hazards regression analysis), including sex, age, bilirubin, albumin, alanine aminotransferase, platelet, HBeAg status, HBV DNA viral load, and liver histology, was performed.
Results
Patient profile
The baseline characteristics of the 27 lamivudinetreated study patients are illustrated in Table 1 . Of these 27 patients, 11 (40%) were positive for HBeAg. The median serum HBV DNA level was 6.6 log copies/ml. Seven patients (25%) were diagnosed as having cirrhosis, with a histological diagnosis in three patients.
Melting curve analysis for the detection of HBV mutants
Domain C (YMDD motif) and domain B (LLA motif) mutants were analyzed via melting curve analysis. The melting peaks of the wild-type and mutant HBV strains were observed at different temperatures (Tm). The melting temperatures of the YIDD and YVDD mutants were approximately 9°C and 2.5°C lower than that of the wild type, respectively ( Fig. 2A) . The LMA mutation resulted in an approximate increase of 7°C in the melting temperature, compared with that of the wildtype LLA (Fig. 2B) .
Detection and semiquantitation of the mutant in total HBV
As shown in Fig. 3A , the YIDD mutant could be detected when HBV DNA levels were 6 log copies/ml. A melting peak height ratio cut-off value of 0.18 had 100% sensitivity and 80% specificity when 10% YIDD mutant in 6 log copies/ml of total HBV DNA was analyzed. Therefore, we used a melting peak height ratio of 0.18 as the cut-off value. A significant linear correlation (r 2 = 0.993, P < 0.001) was observed between the melting peak height ratios and the ratios of mutant/wild-type plasmid DNA when HBV DNA levels were 2, 6, and 10 log copies/ml (Fig. 3B) . YVDD and LMA mutations could be detected at levels as low as 20% and 10% of the total HBV DNA plasmid population when HBV DNA levels were distributed from 2 to 10 log copies/ml, respectively (melting curve not shown).
Detection of YMDD and LLA mutants before lamivudine treatment
The levels of domain C and B mutants were analyzed via a melting curve analysis, in sera from the 27 study 
Detection of YMDD and LLA mutants during lamivudine treatment
Of the 27 patients treated with lamivudine, HBV mutants were detected by FBH assay in four additional patients during an average follow-up of 20 months after lamivudine administration, with the results confirmed by sequence analysis. The changes due to mutation in domains B or C of the five patients with HBV mutants are summarized in Table 2 . In the four patients who developed a YMDD mutant after lamivudine treatment, the mutant was detected between 1 and 3 months after initiating lamivudine treatment, while in the 22 patients without emergence of a mutant, a YMDD mutant was not detected during either this period or the remainder of the follow-up period. In domain B, two patients (patients 2 and 4) exhibited the LMA mutant following emergence of the YIDD mutant ( Table 2 ). Four of the five patients with an HBV mutant (patients 1, 2, 4, and 5) developed breakthrough hepatitis between 12 and 19 months after starting lamivudine treatment. At the stage of mutant emergence, the YIDD mutant was detected in all five patients. In one of the five patients (patient 4), the YVDD mutant replaced the YIDD mutant at the stage of breakthrough hepatitis.
The cumulative incidence rates of YMDD mutant development, reappearance or increase of HBV DNA, and breakthrough hepatitis are illustrated in Fig. 4 . The cumulative incidence rate of YMDD mutant development at 3 months after starting lamivudine treatment was 18%, and no patient developed a YMDD mutant thereafter. The cumulative incidence of the reappearance or re-increase of HBV DNA at 3, 12, and 24 months after starting lamivudine treatment was 0%, 7%, and 15%, respectively. The cumulative occurrence rates of breakthrough hepatitis at 3, 12, and 24 months after starting lamivudine treatment were 0%, 4%, and B Correlation between the ratios of the melting peak heights and the ratios of mutant/wild-type plasmid for HBV DNA levels of 2, 6, and 10 log copies/ml A B months prior to breakthrough hepatitis. Thus, an HBV mutant was detected by the FBH assay as early as 8 months before the reappearance or re-increase of serum HBV DNA. We did not identify any baseline factors that were significantly associated with development of a YMDD mutant, as detected via FBH in the univariate analysis.
Changes in the wild-type and mutant HBV DNA levels in the clinical course of patients with breakthrough hepatitis
The clinical courses and changes in the wild-type and mutant HBV DNA levels of three out of four patients with breakthrough hepatitis are illustrated in Fig. 5 . Wild-type and mutant HBV DNA levels were calculated according to the melting peak height ratio and total HBV DNA level.
In patient 1, the YIDD mutant was detected 3 months after lamivudine administration. Six months after lamivudine administration, the HBV DNA level increased, and the YIDD mutant became predominant. Thirteen months after lamivudine administration, the YIDD mutant increased explosively, and the patient developed breakthrough hepatitis (Fig. 5A) . A similar clinical course was observed in patient 2.
In patient 4, the YIDD mutant was detected 3 months after lamivudine administration. Twelve months after Table  2 ). Plotted is HBV DNA level (log copies/ml) (A, B) or percentage of the total HBV DNA (C) and alanine aminotransferase (ALT) level (IU/ml). LLA mutation (B), monitored via melting curve analysis, is indicated at the bottom 15%, respectively. An HBV mutant was detected via FBH assay as early as 10 months prior to breakthrough hepatitis. The reappearance or re-increase of serum HBV DNA was detected by quantitative PCR only 2 A C B lamivudine administration, the YVDD rather than the YIDD mutant was detected, and breakthrough hepatitis occurred. The YVDD mutant was accompanied by the LMA mutation in domain B (Fig. 5B) . Emergence of the HBV mutant was detected and quantified even during the decreasing phase of HBV DNA level, shortly after the commencement of lamivudine therapy (Fig. 5A,B) .
In patient 5, the YIDD mutant was detected at the initiation of lamivudine treatment. Two months after lamivudine administration, the YIDD mutant was persistently detected via FBH assay, even though the HBV DNA levels were below the detection limit of quantitative PCR using the Amplicor HBV monitor assay (Fig.  5C ).
Discussion
In this study, we established an FBH assay for the detection and quantification of mutations in the YMDD and LLA motifs, and evaluated its clinical usefulness in the clinical course of patients treated with lamivudine.
A melting peak height ratio cut-off value of 0.18 had 100% sensitivity when 10% YIDD mutant in total HBV DNA was analyzed. In previous studies, 7, 22, [24] [25] [26] lamivudine-resistant mutants were detected via sequencing, PCR-RFLP, or line probe assay. 24, 25 The detection limits of these assays were approximately 25%, 20%, and 10% of the total HBV population, respectively. 22, 25, 27 Recently, a highly sensitive RFLP assay 7 and peptide nucleic acid (PNA)-mediated PCR clamping with RFLP 26 have been developed. The detection limits of the highly sensitive RFLP assay and PNA-mediated PCR clamping with RFLP assay were as low as approximately 0.1%-1.0% and 0.01%-0.001% of the total HBV population, respectively. However, the clinical usefulness of these methods remains to be evaluated. Moreover, these methods are time-consuming and labor intensive, because they require a postamplification procedure, such as restriction enzyme digestion and electrophoresis. On the other hand, mutations in the both B and C domains can be detected simultaneously using an FBH assay, within 1 h and in 31 samples at once, without restriction enzyme digestion or electrophoresis. Thus, it is suitable for screening for HBV mutants in a large number of clinical samples. Furthermore, the risk of carryover contamination is minimal, because PCR is performed in a closed glass capillary. 11, 23, 28 The detection of HBV mutants by FBH assay has also been reported by Cane et al. 11 and Whalley et al. 23 They reported that the detection limit of the FBH assay for the YIDD mutant is approximately 20% of the total HBV population. In the present study, 10% YIDD mutant can be detected with a sensitivity of 100% (Fig.  3A) . Furthermore, we demonstrated that the YIDD mutant could be detected via FBH assay even when the titer of the serum HBV DNA was below the detection limit of quantitative PCR (Fig. 5C ), indicating the high sensitivity and potential clinical usefulness of the FBH assay established in this study.
In the present study, we detected HBV mutants within 3 months (1-3 months) , in all four patients who exhibited HBV mutant emergence after lamivudine administration (patients 1-4). It has been reported that lamivudine-resistant HBV mutants can be detected at approximately 2 to 20 months after lamivudine administration. 21, 23, 26 Whalley et al. 23 transiently observed the YIDD mutant at 6 weeks after lamivudine administration. The early detection of lamivudine-resistant HBV mutant demonstrated in the present study suggests that the present assay is of sufficiently high sensitivity for clinical use. With the present assay, the development of HBV mutants during 20 months of therapy can be predicted as early as 3 months after initiating lamivudine treatment.
In the present study, lamivudine-resistant HBV mutants were detected by FBH assay as early as 10 months before the development of breakthrough hepatitis. It has been reported that breakthrough hepatitis occurs approximately 1-11 months after the emergence of mutants. 7, 23, 26, [29] [30] [31] The early detection of lamivudineresistant HBV mutants has become increasingly important for clinicians in predicting breakthrough hepatitis, 27 and could contribute to decisions regarding the introduction of alternative antivirals such as adefovir.
In the present study, we detected a YMDD mutant at the initiation of lamivudine treatment in one patient. Kobayashi et al. 32 also detected a YMDD mutant using a PCR enzyme-linked minisequence assay in 5 of 18 lamivudine-untreated asymptomatic HBV carriers. All of these five patients were positive for anti-HBe and were relatively old (average age, 51 years). Heo et al. 33 detected a YMDD mutant using oligonucleotide chips in 3 of 40 lamivudine-untreated chronic HBV-infected patients. Among these three patients, two were positive for anti-HBe, two had chronic hepatitis, and one had cirrhosis. In the present study, the patient with the mutant was also positive for anti-HBe, and was diagnosed as having cirrhosis. It has been suggested that the lamivudine-resistant mutant might be present at a lower level prior to therapy and might be selected for when antiviral pressure is applied. 32, 34 In the present study using the FBH assay, the cumulative incidence of YMDD mutant development during an average follow-up of 20 months after starting lamivudine treatment was 18%. On the other hand, Liaw et al. 35 reported that the incidence using RFLP was 14% at 12 months and 38% at 24 months after starting lamivudine treatment. Thus, the rate of HBV mutant development observed in the present study was lower than rates reported previously. 35, 36 It has been reported that patients with high HBV DNA levels (e.g., >100 MEq/ml) and HBeAg positivity at baseline are associated with a higher occurrence of YMDD mutations. 30, 37, 38 Thus, the lower rate of lamivudine-resistant HBV mutant development observed in this study may result from the relatively low median HBV DNA level (6.6 log copies/ml).
Because we conducted a retrospective study, a limited number of serum samples from a small number of patients were available. The results indicate the need for future prospective studies in a large number of patients.
In conclusion, the FBH assay developed in the present study is an efficient method to detect and quantify lamivudine-resistant HBV mutants. This assay may contribute to a clinical decision regarding the introduction of alternative antiviral therapies. However, further prospective studies are required to confirm the present observations.
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